This Spinoff Just Got More Interesting
In this video, senior health-care analyst David Williamson discusses Abbott Labs' recent phase 2 hepatitis C drug results and how they are changing the perception of who will control this multibillion-dollar market. Watch and find out what lays ahead for Abbott, or more specifically its spinoff AbbVie, and the rest of the stocks racing to produce the best-in-class next-gen treatment.
Many investors are attracted to Amarin and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
The article This Spinoff Just Got More Interesting originally appeared on Fool.com.Dave Williamson, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.